Amyris | October 23, 2020
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine. The collaboration will combine IDRI's RNA vaccine platform, including IDRI's proprietary nanostructured lipid carrier (NLC) platform, with Amyris's semi-synthetic squalene. This has the potential to offer differentiated advantages over other RNA vaccines, including superior scalability, efficacy, and sustainability. Amyris will co-own intellectual property developed to create the COVID-19 vaccine, any rights in any combination of IDRI materials and Amyris squalene, the pre-clinical and Phase I clinical trial data, and the Clinical Study Report.
CELL AND GENE THERAPY
Biocytogen | June 23, 2021
Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, the organization autonomously created mouse stages for completely human neutralizer disclosure, RenMab® and RenLite®, that have free protected innovation rights. With the execution of these stages, Biocytogen has advanced from an agreement research association (CRO) into a global biotechnology organization with aptitude crossing the whole cycle of new drug R&D, including immune response drug target check, high-throughput single B cell counter acting agent revelation innovation, in vivo drug viability assessment utilizing adapted objective mice, and clinical turn of events.
Genetic engineering of RenMab® and RenLite® mice has empowered the integration of Biocytogen's innovative qualities into a one of a kind enormous scope R&D plan for the revelation of helpful antibodies, a drive named the RenMice HiTS Platform. The HiTS Platform means the organization's obligation to finish high-productivity counter acting agent revelation and in vivo drug viability screening of in excess of 1,000 neutralizer targets in the following not many years, zeroing in on the disclosure of first-in-class and top tier drug targets. Through the ID of immune response drives that have been confirmed for adequacy in creature models, Biocytogen has set up co-improvement associations with in excess of twelve biotechnology and pharmaceutical organizations.
Genelux Corporation | September 29, 2021
Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses.
According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refractory ovarian cancer. Newsoara also shall have exclusive rights in Greater China to Genelux's proprietary oncolytic virus platform, and the parties will collaborate on the development of novel oncolytic immunotherapeutics.
Newsoara, at its cost and expense, will be responsible for development and commercialization and will have the future right to manufacture licensed products in Greater China. The parties also will collaborate on a Phase 2 clinical trial for the intravenous delivery of Olvi-Vec in a new indication using clinical sites in China and the U.S. Newsoara will be responsible for all trial costs.
Under terms of the agreement, Genelux will receive up-front and near-term payments totaling $11 million and will be eligible to receive additional per-product payments of up to $160.5 million, contingent on certain development, regulatory and commercial milestones, plus tiered royalties on net sales ranging from mid-single-digit to mid-double-digit percentages. Genelux shall have an exclusive license outside of Greater China to oncolytic virus products derived by Newsoara and will pay Newsoara milestones and royalties on sales of any such products which Genelux elects to develop.
We are delighted to be working with Newsoara on developing Olvi-Vec, as well as on our broader collaboration. It is a dynamic organization with a commitment to advancing cutting-edge therapeutics, whose strength in research, development and manufacturing in China is a perfect complement to our focus on the discovery and clinical development of novel virotherapies. Together we look forward to accelerating the development of Olvi-Vec and to strengthening and broadening our pipeline of next-generation oncolytic viral immunotherapies.
- Thomas Zindrick, J.D., President and CEO of Genelux.
About Olvimulogene Nanivacirepvec (Olvi-Vec)
Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and therapeutic potential. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Olvi-Vec has been administered to more than 150 patients in clinical studies. In these studies, Olvi-Vec was generally well tolerated and the data provided evidence of clinical benefit.
Newsoara is a clinical-stage biopharmaceutical company with the mission to develop and commercialize life changing medicines for the treatment of patients with cancer, autoimmune, metabolic and other major diseases in China and around the world. With fully integrated drug discovery, CMC and clinical development capabilities, Newsoara has built a robust and broad pipeline for treating major diseases with unmet needs. Newsoara has assembled a world-class management team with extensive experience in novel drug development that is motivated to improve and impact human health worldwide.
About Genelux Corporation
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. The core of Genelux's discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.